@Article{info:doi/10.2196/38680,
author="Su, Benli
and Chen, Yu
and Shen, Xingping
and Guo, Jianchao
and Ding, Yuchen
and Ma, Xiao
and Yang, Yuxin
and Liu, Dongfang",
title="Effectiveness of the Lilly Connected Care Program in Improving Glycemic Management Among Patients With Type 2 Diabetes in China: Retrospective Real-world Study",
journal="J Med Internet Res",
year="2023",
month="Apr",
day="25",
volume="25",
pages="e38680",
keywords="type 2 diabetes mellitus; T2DM; diabetes management; Lilly Connected Care Program; LCCP; hemoglobin A1c; real-word study",
abstract="Background: Type 2 diabetes mellitus (T2DM) is a worldwide public health concern. Mobile health management platforms could be a potential way to achieve effective glycemic control. Objective: This study aimed to evaluate the real-world effectiveness of the Lilly Connected Care Program (LCCP) platform in glycemic control among patients with T2DM in China. Methods: This retrospective study included Chinese patients with T2DM (aged ≥18 years) from April 1, 2017, to January 31, 2020, for the LCCP group and from January 1, 2015, to January 31, 2020, for the non-LCCP group. Propensity score matching was used to match the LCCP and non-LCCP groups to reduce confounding, with covariates including age, sex, the duration of diabetes, baseline hemoglobin A1c (HbA1c), and the number of oral antidiabetic medication classes. HbA1c reduction over 4 months, the proportions of patients achieving an HbA1c reduction of ≥0.5{\%} or ≥1{\%}, and the proportions of patients reaching to target HbA1c level of ≤6.5{\%} or <7{\%} were compared between the LCCP and non-LCCP groups. Multivariate linear regression was used to assess factors associated with HbA1c reduction. Results: A total of 923 patients were included, among whom 303 pairs of patients were well matched after propensity score matching. HbA1c reduction during the 4-month follow-up was significantly larger in the LCCP group than the non-LCCP group (mean 2.21{\%}, SD 2.37{\%} vs mean 1.65{\%}, SD 2.29{\%}; P=.003). The LCCP group had a higher proportion of patients with an HbA1c reduction of ≥1{\%} (209/303, 69{\%} vs 174/303, 57.4{\%}; P=.003) and ≥0.5{\%} (229/303, 75.6{\%} vs 206/303, 68{\%}; P=.04). The proportions of patients reaching the target HbA1c level of ≤6.5{\%} were significantly different between the LCCP and non-LCCP groups (88/303, 29{\%} vs 61/303, 20.1{\%}; P=.01), whereas the difference in the proportions of patients reaching the target HbA1c level of <7{\%} was not statistically significant (LCCP vs non-LCCP: 128/303, 42.2{\%} vs 109/303, 36{\%}; P=.11). LCCP participation and higher baseline HbA1c were associated with a larger HbA1c reduction, whereas older age, longer diabetes duration, and higher baseline dose of premixed insulin analogue were associated with a smaller HbA1c reduction. Conclusions: The LCCP mobile platform was effective in glycemic control among patients with T2DM in China in the real world. ",
issn="1438-8871",
doi="10.2196/38680",
url="https://www.jmir.org/2023/1/e38680",
url="https://doi.org/10.2196/38680",
url="http://www.ncbi.nlm.nih.gov/pubmed/37097724"
}